NASDAQ$AMED
Amedisys Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Amedisys reported mixed results with revenue increase and net income decrease for Q4 2021.
Amedisys reported a slight increase in net service revenue for Q4 2021, rising to $559.3 million from $550.7 million in the same period of 2020. However, net income attributable to Amedisys, Inc. decreased to $34.0 million compared to $45.2 million in the previous year. The company issued 2022 guidance, anticipating adjusted net service revenue to be in the range of $2.330 billion to $2.365 billion and adjusted EBITDA in the range of $275 million to $285 million.
- Net service revenue increased to $559.3 million from $550.7 million year-over-year.
- Net income attributable to Amedisys, Inc. decreased to $34.0 million from $45.2 million year-over-year.
- Adjusted net income attributable to Amedisys, Inc. was $38.8 million, compared to $49.5 million in 2020.
- The company issued 2022 guidance with adjusted net service revenue anticipated between $2.330 billion and $2.365 billion.
Headline financials
Revenue & EPS history
Amedisys · Revenue · Quarterly
$559M
Forward guidance
Amedisys anticipates adjusted net service revenue to be in the range of $2.330 billion to $2.365 billion and adjusted EBITDA in the range of $275 million to $285 million.
Tailwinds
- Adjusted net service revenue is anticipated to be in the range of $2.330 billion to $2.365 billion.
- Adjusted EBITDA is anticipated to be in the range of $275 million to $285 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $5.23 to $5.45 based on an estimated 33.2 million shares outstanding.
- Company continues to lead the industry in quality.
- Company is working through new and innovative workforce optimization initiatives.
Headwinds
- Guidance excludes the effects of any future acquisitions and potential share repurchases, if any are made.
- COVID-19 has continued to impact the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa.
- Any future regulations or government interventions could impact the company's ability to achieve this guidance.
- Spike in clinicians and business development staff on quarantine could impact the company's ability to achieve this guidance.
- Staffing shortages due to current and proposed federal, state and local vaccine mandates could impact the company's ability to achieve this guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2021
-0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
46%
32 / 70 earnings
Positive
+25.6%
Q2 2014
Best reaction
-25.3%
Q3 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.2% | +1.0% | — | |
| Q1 2025 | +0.2% | -0.8% | -1.6% | |
| Q4 2024 | +0.1% | +0.6% | +1.5% | |
| Q3 2024 | +0.9% | -3.4% | -10.4% | |
| Q2 2024 | +0.0% | +0.5% | -0.2% | |
| Q1 2024 | +0.0% | +0.8% | +5.5% | |
| Q4 2023 | +0.9% | +0.6% | -1.6% | |
| Q3 2023 | -0.8% | -1.1% | +1.8% | |
| Q2 2023 | -0.6% | -0.2% | +2.5% | |
| Q1 2023 | +4.2% | +3.9% | +2.8% | |
| Q4 2022 | +5.4% | +2.2% | -23.6% | |
| Q3 2022 | -9.0% | -4.2% | -10.7% | |
| Q2 2022 | -3.8% | +0.9% | -4.5% | |
| Q1 2022 | +0.4% | -3.3% | -10.5% | |
| Q4 2021 | +5.8% | +14.5% | +18.4% | |
| Q3 2021 | +0.1% | +1.7% | -20.2% | |
| Q2 2021 | -22.8% | -22.9% | -29.3% | |
| Q1 2021 | +0.2% | — | — | |
| Q4 2020 | -6.2% | — | — | |
| Q3 2020 | -1.9% | — | — | |
| Q2 2020 | +3.7% | — | — | |
| Q1 2020 | -3.3% | — | — | |
| Q4 2019 | -2.1% | — | — | |
| Q3 2019 | -1.5% | — | — | |
| Q2 2019 | -1.9% | — | — | |
| Q1 2019 | -6.3% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | +17.3% | — | — | |
| Q2 2018 | +11.1% | — | — | |
| Q1 2018 | +7.2% | — | — | |
| Q4 2017 | +2.3% | — | — | |
| Q3 2017 | +4.8% | — | — | |
| Q2 2017 | -20.9% | — | — | |
| Q1 2017 | +4.4% | — | — | |
| Q4 2016 | +4.7% | — | — | |
| Q3 2016 | -10.1% | — | — | |
| Q2 2016 | -7.1% | — | — | |
| Q1 2016 | -7.0% | — | — | |
| Q4 2015 | +12.3% | — | — | |
| Q3 2015 | +10.8% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | +6.0% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | +16.2% | — | — | |
| Q2 2014 | +25.6% | — | — | |
| Q1 2014 | -1.0% | — | — | |
| Q4 2013 | -10.0% | — | — | |
| Q3 2013 | -25.3% | — | — | |
| Q2 2013 | +17.8% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q4 2012 | -8.7% | — | — | |
| Q3 2012 | -5.0% | — | — | |
| Q2 2012 | +12.5% | — | — | |
| Q1 2012 | -1.2% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | -23.8% | — | — | |
| Q2 2011 | -10.7% | — | — | |
| Q1 2011 | -6.4% | — | — | |
| Q4 2010 | -8.0% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q2 2010 | -7.9% | — | — | |
| Q1 2009 | -4.3% | — | — | |
| Q1 2010 | +2.6% | — | — | |
| Q4 2007 | -1.3% | — | — | |
| Q4 2009 | -1.3% | — | — | |
| Q3 2008 | -5.7% | — | — | |
| Q3 2009 | -5.7% | — | — | |
| Q4 2008 | +7.6% | — | — | |
| Q2 2008 | +7.6% | — | — | |
| Q2 2009 | +7.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro